Myriad Genetics (MYGN) Total Liabilities (2010 - 2026)

Myriad Genetics has disclosed Total Liabilities across 17 years of filings, most recently posting $336.3 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 11.65% year-over-year to $336.3 million; the TTM figure through Mar 2026 stood at $336.3 million (up 11.65% YoY), while the FY2025 annual figure was $338.6 million, up 3.71% from the prior year.
• Total Liabilities fell to $336.3 million in Q1 2026, from $338.6 million in the prior quarter.
• Over the last five years, Total Liabilities for MYGN reached as high as $465.7 million in Q3 2023 and fell as low as $262.8 million in Q2 2022.
• The 5-year median for Total Liabilities is $336.3 million (2026), against an average of $340.2 million.
• Annual changes were most pronounced in 2022 — Total Liabilities plunged 42.61% — and 2023, when it jumped 71.99%.
• A 5-year view of Total Liabilities shows it stood at $312.9 million in 2022, then increased by 16.11% to $363.3 million in 2023, then slipped by 10.13% to $326.5 million in 2024, then climbed by 3.71% to $338.6 million in 2025, then retreated by 0.68% to $336.3 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $336.3 million, $338.6 million, and $355.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.